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Abstract
Introduction: Lysyl oxidase-like 2 (LOXL2) is a matrix-remodeling enzyme that has been shown to play a key role
in invasion and metastasis of breast carcinoma cells. However, very little is known about its role in normal tissue
homeostasis. Here, we investigated the effects of LOXL2 expression in normal mammary epithelial cells to gain
insight into how LOXL2 mediates cancer progression.
Methods: LOXL2 was expressed in MCF10A normal human mammary epithelial cells. The 3D acinar
morphogenesis of these cells was assessed, as well as the ability of the cells to form branching structures on
extracellular matrix (ECM)-coated surfaces. Transwell-invasion assays were used to assess the invasive properties of
the cells. Clinically relevant inhibitors of ErbB2, lapatinib and Herceptin (traztuzumab), were used to investigate the
role of ErbB2 signaling in this model. A retrospective study on a previously published breast cancer patient dataset
was carried out by using Disease Specific Genomic Analysis (DSGA) to investigate the correlation of LOXL2 mRNA
expression level with metastasis and survival of ErbB2-positive breast cancer patients.
Results: Fluorescence staining of the acini revealed increased proliferation, decreased apoptosis, and disrupted
polarity, leading to abnormal lumen formation in response to LOXL2 expression in MCF10A cells. When plated
onto ECM, the LOXL2-expressing cells formed branching structures and displayed increased invasion. We noted
that LOXL2 induced ErbB2 activation through reactive oxygen species (ROS) production, and ErbB2 inhibition by
using Herceptin or lapatinib abrogated the effects of LOXL2 on MCF10A cells. Finally, we found LOXL2 expression
to be correlated with decreased overall survival and metastasis-free survival in breast cancer patients with ErbB2-
positive tumors.
Conclusions: These findings suggest that LOXL2 expression in normal epithelial cells can induce abnormal
changes that resemble oncogenic transformation and cancer progression, and that these effects are driven by
LOXL2-mediated activation of ErbB2. LOXL2 may also be a beneficial marker for breast cancer patients that could
benefit most from anti-ErbB2 therapy.
Introduction
Lysyl oxidase-like 2 (LOXL2) is one of five members of
the lysyl oxidase (LOX) family of extracellular matrix
proteins and mediates the cross-linking of stromal col-
lagens and elastin [1-3]. We previously showed that
LOXL2 expression is clinically correlated with increased
metastasis and poor survival in breast cancer patients
with estrogen receptor (ER)-negative tumors [4].
Consistent with this, other studies found LOXL2 protein
levels to be higher in poorly differentiated breast carci-
nomas, and elevated LOXL2 mRNA was observed in
invasive and metastatic breast cancer cell lines [5,6]. We
showed that LOXL2 plays a critical role in breast cancer
progression, and further demonstrated that genetic, che-
mical, or antibody inhibition of LOXL2 significantly
reduced the size and number of metastases in the lungs,
liver, and bone through blocking the effects of extracel-
lular LOXL2 on matrix remodeling and cell invasion [4].
In accordance with our findings, Barry-Hamilton et al.
[7] demonstrated efficacy of an LOXL2-targeting anti-
body in reduction of bone and soft tissue metastases
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after intracardiac injection of human breast cancer cells
[7]. This antibody is now in phase II clinical trials.
Upregulation of LOXL2 is also associated with poor
prognosis in patients with squamous cell, colon, and
esophageal cancers [8,9]. Furthermore, LOXL2 is linked
to drug resistance in pancreatic cancer cells [10] and
promotes gastric cancer metastasis [11]. Thus, LOXL2 is
likely to be an excellent drug target in many cancer
types [12].
Despite the mounting evidence suggesting a critical
role for LOXL2 in metastasis, very little is known about
its function during development or its role in normal
tissue homeostasis. LOXL2 mRNA was detected at low
levels in heart, lung, and kidney, and at high levels in
the prostate, uterus, and placenta [13]. However, LOXL2
protein levels were very low in all normal adult tissues
[7]. As a result, no deleterious side effects have been
observed in response to LOXL2 inhibition [4,7].
In the adult mammary gland, epithelial cells are orga-
nized into ducts and lobules. The lobules comprise mul-
tiple mammary acini, and each lobule has a mammary
duct connecting the lobules to the nipple. Normal acini
have lumens formed by a single layer of polarized lumi-
nal epithelial cells, surrounded by myoepithelial cells,
and finally, the basement membrane. Epithelial cells
grown on plastic do not accurately reflect the in vivo
microenvironment of the mammary gland, highlighting
the importance of studying tumorigenesis by using a
three-dimensional (3D) model mimicking normal mam-
mary epithelial development.
Studying LOXL2 function in normal cells can provide
information about its role in cancer; thus, here we used
the well-established MCF10A acini assay [14] as a 3D
model to investigate the role of LOXL2 in mammary
epithelial acini formation and to provide novel insights
into the molecular events regulated by LOXL2.
We showed that overexpression of LOXL2 induces
invasive branching structures on cells plated onto extra-
cellular matrix (ECM) and increases invasiveness of the
cells. LOXL2 induction also causes aberrant acini devel-
opment by interfering with apoptosis, proliferation, and
polarization, and these LOXL2-mediated effects are atte-
nuated when ErbB2 signaling is inhibited. In this article,
we are the first to demonstrate that LOXL2 induces
phosphorylation of ErbB2 through the production of
reactive oxygen species (ROS). Moreover, we showed
that LOXL2 expression correlates with metastasis and
poor survival in ErbB2-positive breast cancer patients.
Materials and methods
Cell lines and cell culture
All cell lines used in this study were obtained from
American Type Culture Collection. Human MCF10A
normal mammary epithelial cells were grown in F12/
DMEM (Invitrogen) media supplemented with 5% horse
serum (HS, Invitrogen), 0.5 μg/ml hydrocortisone
(Sigma), 10 μg/ml insulin (Sigma), 100 ng/ml cholera
toxin (Sigma), and 20 ng/ml EGF (Peprotech). MCF10A
cell lines used were cultured for no more than 20 pas-
sages. Human MDA-MB-361 breast cancer cells were
grown in F12/DMEM (Invitrogen) media supplemented
with 20% fetal calf serum (Invitrogen). Human MDA-
MB-231 breast cancer cells were grown in DMEM (Invi-
trogen) media supplemented with 10% fetal calf serum
(Invitrogen).
Generation of cell lines
For overexpression of the LOXL2 protein, the human
LOXL2 gene was amplified by polymerase chain reaction
(PCR) and cloned into the pBABE retroviral vector by
using the following primers: 5’-CGC GGA TCC ATG
GAG AGG CCT CTG TGC TCC CAC-3’, 3’-CGC GTC
GAC TTA CTG CGG GGA CAG CTG GTT GTT
TAA GAG C-5’. MCF10A cell line was infected with
retroviruses expressing the pBABE vector containing
LOXL2 (10A L2), or parental pBABE retroviral vector as
a control (10A cont).
Quantitative real-time PCR
Total RNA was isolated from cell pellets by using
RNeasy Mini Kits (Qiagen). RNase treatment and cDNA
synthesis were done by using RNaseOUT and M-MLV
Superscript (Invitrogen), according to manufacturer’s
instructions. b-actin was used as an internal control.
The following primers were used for the analysis of
LOXL2, b-actin, E-cadherin, Vimentin, SNAI1, SNAI2,
a-SMA, TWIST, and N-cadherin: LOXL2 forward,
5’-CTG CCA CAT AGG TGG TTC T-3’; LOXL2
reverse, 5’-TGG CAT TCG TTC AGA CTC AG-3’. b-
actin forward, 5’-GAG GCC CAG AGC AAG AGA
GG-3’. b-actin reverse, 5’-TAC ATG GCT GGG GTG
TTG AA-3’. E-cadherin forward, 5’-TGG AGG AAT
TCT TGC TTT GC-3’; E-cadherin reverse, 5’-CGC
TCT CCT CCG AAG AAA C-3’. Vimentin forward,
5’-CTT CGC CAA CTA CAT CGA CA-3’; Vimentin
reverse, 5’-CGG CCA GCA GGA TCT TAT T-3’.
SNAI1 forward, 5’-AGG ATC TCC AGG CTC GAA
AG-3’; SNAI1 reverse, 5’-TCG GAT GTG CAT CTT
GAG G-3’. SNAI2 forward, 5’-TCC GAA GCC AAA
TGA CAA AT-3’; SNAI2 reverse, 5’-TGT GTG TGC
ATA TGT GTG TGT G-3’. a-SMA forward, -5’-CCC
TGA AGT ACC CGA TAG AAC A-3’; a-SMA reverse,
-5’-GGC AAC ACG AAG CTC ATT G-3’. TWIST for-
ward, 5’-GGG CCG GAG ACC TAG ATT-3’; TWIST
reverse, 5’-TTC TGA ATT GTA TCA CAC CTT CTC
A-3’. N-cadherin forward, 5’-GTG CTC AGG CTG
TGG ACA TA-3’; N-cadherin reverse, 5’-CTG CAC
TTT GAT GAT GAA TTC TG-3’.
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The following reaction cycle was used: 95°C for 10
minutes, followed by 40 cycles of 95°C for 15 seconds,
60°C for 30 seconds, 72°C for 30 seconds, and a final
step of 72°C for 10 minutes. The PCR was performed by
using an Applied Biosystems 7900HT Fast Real-Time
PCR system (Applied Biosystems, Carlsbad, CA, USA),
or Roche LightCycler480II (Roche Applied Science).
2D and 3D proliferation assays
The 2D proliferation on plastic and 3D proliferation in
Matrigel of the cells were assessed by using the CellTi-
ter 96® AQueous One Solution Cell Proliferation Assay
(Promega), according to the manufacturer’s instructions.
Cells were plated in triplicate in 96-well plates at 2,000
cells per well, either in 100 μl of media or in 50 μl of
Matrigel (BD Biosciences). All readings were normalized
to day 0 readings.
Western blotting
All cells were lysed in 1% NP40 buffer supplemented
with 10 μg/ml aprotinin (Sigma) and 10 μg/ml leupeptin
(Sigma).
Conditioned medium (CM) was obtained as previously
described [15]. For lysate preparation, 350,000 cells were
plated on Matrigel-coated six-well plates. After over-
night incubation at 37°C, 5% CO2/20% O2, the cells
were serum-starved for 3 hours and then serum-blasted
for 15 minutes before collection for maximal signaling
activation.
For drug treatments, cells were plated out as described
earlier, and 3 hours after plating, the cells were exposed
to lapatinib or Herceptin at the indicated concentra-
tions. Equivalent amounts of DMSO or human kappa
IgG (Sigma) were added to the cells as a control for
lapatinib and Herceptin, respectively. After overnight
incubation with the drugs, the cells were serum-starved
for 3 hours and then serum-blasted for 15 minutes in
presence of drug before collection.
For catalase treatment with or without recombinant
human LOXL2 (rhLOXL2), the cells were plated as
described earlier. After overnight incubation in the
absence of treatment, the cells were serum-starved for 3
hours and then subjected the following combination of
treatments for 15 minutes before collection: 200 U/ml
catalase (Sigma), 50 nM recombinant human LOXL2
(rhLOXL2, R&D Systems), 200 U/ml catalase, and 50
nM rhLOXL2.
For rhLOXL2 treatment only, 700,000 cells were pla-
ted on polyacrylamide-crosslinked 50-mm-diameter cov-
erslips that were coated with Matrigel by using a
previously published protocol [16]. The 50 nM
rhLOXL2 was added onto one set of 10A control cells.
After overnight incubation at 37°C, 5% CO2/20% O2, the
cells were serum-starved for 3 hours and then serum-
blasted for 15 minutes before collection.
Proteins were separated with NuPAGE Novex Bis-Tris
10% gels or 7% Tris-Acetate gels (Invitrogen), trans-
ferred to polyvinylidene difluoride membranes (Milli-
pore), and immunoblotted with antibodies specific for
human ErbB2, pErbB2, EGFR, pEGFR, Erk1/2 (MAPK),
pErk1/2 (pMAPK), Akt, and pAkt (all Cell Signaling), or
human LOXL2 (Abcam). Hsc70 or b-actin (Abcam) was
used as a loading control.
Densitometry analysis was carried out by using
ImageJ64, and intensities of bands were corrected to
control lanes for each individual blot. All analyses were
carried out on at least three individual repeats of the
experiment.
Acini assay
10A cont and 10A L2 cells were plated on top of a thin
layer of 50-μl Matrigel in eight-well chamber slides, at a
density of 10,000 cells/ml in 400 μl of 2% Growth Factor
Reduced Matrigel without phenol red (BD Biosciences) in
DMEM/F-12 media supplemented with 2% HS, 0.5 μg/ml
hydrocortisone, 10 μg/ml insulin, 100 ng/ml cholera
toxin, and 20 ng/ml EGF (Gibco/Invitrogen). The cul-
tures were allowed to grow for 8, 10, and 13 days, and
then fixed with 2% paraformaldehyde (PFA, Invitrogen)
in PBS at room temperature.
For drug-treated cultures, lapatinib dissolved in 0.1%
DMSO or Herceptin dissolved in PBS was added to cells
at day 6 (10A cont+lap, 10A L2+lap; 10A cont+her, 10A
L2+her), and 0.1% DMSO or an equivalent amount of
human IgG was added as a control to lapatinib and Her-
ceptin, respectively (10A cont+DMSO, 10A L2+DMSO;
10A cont+her, 10A L2+her). All assay media, with or
without treatments, were changed every 3 to 4 days.
Acini were permeabilized with 0.5% Triton X-100
(Invitrogen), washed thoroughly with glycine buffer
(0.1 M NaCl, 0.1 M glycine in PBS), blocked in IF buffer
(0.1% bovine serum albumin (BSA), 0.2% Triton X-100,
0.05% Tween20, 130 mM NaCl in PBS) containing 10%
goat serum (Invitrogen) and incubated with primary anti-
bodies diluted in blocking buffer. Samples were then
washed with IF buffer and incubated with appropriate
Alexa-conjugated secondary antibodies (Invitrogen) in
10% goat serum/IF buffer. Nuclei were counterstained
with DAPI (Invitrogen). Slides were then mounted under
coverslips with Fluorescent Mounting Medium (Invitro-
gen) and visualized with confocal microscopy (Zeiss
LSM710) by using a 63 × oil objective. Primary antibo-
dies used were Ki-67, activated caspase-3, GM130,
E-cadherin, and laminin V (all from Abcam). All photos
taken were of midsections of acini. Photos presented here
are representative of the overall phenotype in each
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experimental condition; quantifications were carried out
on at least 20 acini per experimental repeat.
Transwell invasion assay
Matrigel transwell invasion assays were carried out by
using BD Bio-coat Matrigel Invasion Chambers (BD
Biosciences), according to the manufacturer’s instruc-
tions. Cells were serum-starved overnight before plating,
and the normal culture media were added to the bottom
chambers as chemoattractant. Plates were incubated at
normal culture conditions for 24 hours before noninvad-
ing cells were removed from the inside of inserts, and
membranes fixed and stained. Total number of invaded
cells was counted under a light microscope (Nikon Dia-
phot 300).
Branching assay
The 350,000 cells were plated on Matrigel-coated six-
well plates. For treated cells, lapatinib (DMSO as con-
trol) or Herceptin (human kappa IgG as control) were
added to cell cultures 3 hours after plating. Cells were
then incubated overnight and viewed under a micro-
scope (Leica DM1L).
Soft agar assay
To test anchorage-independent growth in soft agar,
3 × 104 cells were suspended in 2 ml of 0.4% low-melting-
point agarose (Invitrogen) in culture medium and were
overlaid over 2 ml of 0.8% low-melting-point agarose in
culture medium in a six-well plate. Culture medium was
added to the top once the agarose had solidified, and
plates were incubated at 37°C, 5% CO2/21% O2. After 3
weeks in culture, colonies were stained with 0.1% crystal
violet and destained with PBS. Colonies with more than
20 cells were scored with a light microscope (Nikon
Diaphot 300).
Activity assay
Activity assays using a fluorescence-based LOX family
enzymatic-activity assay measuring H2O2 (Abcam,
Ab112139) were carried out according to manufacturer’s
instructions except using Matrigel as the substrate.
Then 5 μl of concentrated conditioned media was added
to the reaction mixture on a thin layer of Matrigel in a
96-well dish.
Patient data analysis
Gene-expression microarray data from a previously pub-
lished NKI cohort [17] was first transformed by using
Disease Specific Genomic Analysis (DSGA) [18] to iden-
tify the extent of deviation from a Healthy State Model
(HSM), defined by 13 normal breast samples [18]. This
provided gene-expression levels in tumors that are rela-
tive to the control normal tissue data. Of 295 tumors,
51 were found to express high levels of ErbB2, and a
Kaplan-Meier survival curve is constructed from this
subset of ErbB2-positive tumors. Shown here is the
overall and metastasis-free survival of patients with
Her2/ErbB2-positive tumors (n = 51) separated into low
and high LOXL2 expression.
Validation was carried out by combining another two
previously published NKI cohorts [19,20]. Samples were
run on Affymetrix U133a chips according to manufac-
turer’s instructions, and data were obtained by using
MAS5 parameters with global scaling set to 600. Of 344
tumors, 88 were found to express high levels of ErbB2,
and Kaplan-Meier survival curves were constructed
from this subset of ErbB2-positive tumors. Shown here
is the overall and metastasis-free survival of patients
with Her2/ErbB2-positive tumors (n = 88) separated
into low and high LOXL2 expression.
Statistical analysis
Data were analysed by using the Student t test, and con-
sidered significant at P ≤ 0.05. All statistical tests were
two sided. Bar graphs represent the mean and standard
error across independent experimental repeats, and all
experiments were performed at least three independent
times. Statistical significance representations: *P < 0.05;
**P < 0.01; ***P < 0.001; and ****P < 0.0001.
Results and Discussion
Expression of LOXL2 in human MCF10A normal mammary
epithelial cells
We first investigated the potential impact of LOXL2
expression in normal breast epithelial morphogenesis.
The MCF10A cell line was derived from normal human
mammary epithelium that had undergone spontaneous
immortalization without transformation, and is not
tumorigenic [21]. With this normal epithelial cell line,
we investigated how LOXL2 promotes tumor progres-
sion. We infected MCF10A cells with pBABE retroviral
vector containing a LOXL2 cDNA to generate LOXL2-
expressing cells (10A L2) and generated control cells
(10A cont) by infecting wild-type MCF10A cells with
the parental pBABE retroviral vector. MCF10A cells are
known to show genetic drift [22]; however, we main-
tained cells at a passage lower than 20, as we noted
altered cell phenotype above passage 30, consistent with
a previous report [22].
Western blot analysis showed that secreted LOXL2 was
upregulated in 10A L2 cells relative to control cells, and
comparable with those in the human breast cancer cell line
MDA-MB-231 (Figure 1A). Two bands of approximately
95 kDa and 65 kDa were observed, the 95-kDa band repre-
senting the long form of LOXL2 that is commonly
reported in cancer cells, and the fainter 65-kDa band that
may correspond to the proteolytically modified short form
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of LOXL2 protein [9,23]. Quantitative real-time PCR indi-
cated that LOXL2 mRNA expression was significantly
increased in 10A L2 cells (P < 0.05; Figure 1B).
Previous reports suggested that manipulated LOXL2
expression in normal mammary epithelial cells [24] and
MDA-MB-231 human breast cancer cells [25] can alter
cell morphology on 2D tissue-culture plastic. However,
we did not observe any significant phenotypic alterations
when compared with 10A wild-type cells at passage 3
(Figure 1C), consistent with our previous findings with
MDA-MB-231 and 4T1 cells, in which no obvious
changes in 2D morphology were noted [4]. These
Figure 1 Manipulation of LOXL2 expression levels in human MCF10A normal mammary epithelial cells. (A) Western blot of secreted
LOXL2 in CM generated from MDA MB-231 cells (MDA 231), MCF10A cells infected with LOXL2 (10A L2) and vector alone (10A cont) revealed
that LOXL2 protein expression was upregulated in the 10A L2 cells to a level similar to that detected in MDA cells. b-Actin was used as a
loading control. (B) Quantitative real-time PCR (qRT-PCR) of LOXL2 mRNA levels in manipulated MCF10A cells showed that LOXL2 mRNA levels
were upregulated in 10A L2 cells. P = 0.009. (C) Morphologies of the manipulated MCF10A cells compared with WT cells showed that
upregulation of LOXL2 did not produce significant alterations on cells plated on 2D tissue-culture plastic. Cells were viewed under a microscope
(Leica DM1L), and representative images were taken. (D) 2D MTS proliferation assay of manipulated MCF10A cells suggested that when cultured
on plastic, LOXL2 expression did not alter proliferation of the 10A cells. Error bars represent SEM for three independent experiments. (E) 3D MTS
proliferation assay of manipulated MCF10A cells with manipulated LOXL2 expression plated within Matrigel suspension suggested that increased
LOXL2 expression increases proliferation of the 10A cells in 3D. Error bars represent SEM for three independent experiments. P = 0.034 for day 6.
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findings suggest variable effects of LOXL2 on 2D mor-
phology that may be cell-line specific or sensitive to
cell-culture methods.
To assess the effects of LOXL2 on 2D proliferation,
we carried out MTS assays. Increased secretion of
LOXL2 did not affect 2D cell proliferation on plastic
(Figure 1D). In contrast, we observed a significant
increase in proliferation of 10A L2 cells compared with
10A cont cells after 6 days of culture in Matrigel sus-
pension (P < 0.05; Figure 1E). Taken together, these
results suggest that the microenvironment is important
for the effects of LOXL2.
LOXL2 expression disrupts normal breast epithelial acini
formation
The role of LOXL2 in 3D development of normal breast
epithelial cells was assessed by using the well-character-
ized MCF10A acini assay [14], in which cells are cul-
tured on top of a layer of recombinant basement
membrane (Matrigel) within a Matrigel suspension. The
10A cont and 10A L2 cells were compared for their
ability to form acini structures in Matrigel over a 13-day
period. In 10A cont acini, lumen formation was initiated
by apoptosis, as assessed by the expression of activated
caspase-3, in the middle of the acinar structure at day 8,
as expected. In contrast, significantly fewer central cells
in 10A L2 acinar structures expressed activated caspase-
3 (P < 0.001; Figure 2A). Consistent with our finding, it
was previously reported that genetic silencing of LOXL2
increased apoptosis in carcinoma tumor growth [26].
During normal acini structure development, prolifera-
tion ceases after 12 days of culture when lumen forma-
tion is complete [14]. In this study, we investigated the
effect of LOXL2 overexpression on proliferation through
Ki67 immunofluorescence staining. After 13 days in cul-
ture, control acini formed lumens and had significantly
fewer proliferating cells, whereas proliferating cells were
still present in 10A L2 acini (P < 0.001; Figure 2B). This
sustained proliferation observed may explain the larger
size of the 10A L2 acini. Moreover, 10A L2 acini did
not have fully evacuated lumens (Figure 2B and 2D),
similar to acini responding to oncogene activation [27].
The increased proliferation was consistent with the
growth of the cells in Matrigel (Figure 1E). These results
stress the importance of the surrounding microenviron-
ment for studying cellular processes in culture [28],
especially those involved in cancer progression [15,29].
Mammary epithelial polarization is an important pro-
cess during acini formation. One of the characteristics
of polarization is the redistribution of cellular organelles.
The Golgi apparatus, in particular, is aligned on the api-
cal side of polarized epithelial cells [30]. Immunofluores-
cence staining of 10A cont acini for GM130, a Golgi
marker, revealed that by day 10 of culture, the Golgi
apparatus in the outer cells of the acini was aligned
toward the lumen, forming a classic ring-like pattern, as
previously described [31,32]. In contrast, cells in the
10A L2 acini failed to polarize, as evidenced by the dis-
organized GM130 staining (P < 0.001; Figure 2C). It was
recently proposed that epithelial cell polarity may play a
major role in tumor initiation and progression [33], and
that LOXL2 decreases the expression of cell-polarity
complexes in basal-like breast carcinoma cells [34]. This
provides a link between our previous report of LOXL2
mediating breast cancer progression [4], and our current
report that LOXL2 expression drives abnormal cell
polarity in normal mammary epithelial cells.
As acinar lumen filling is a characteristic of oncogenic
transformation [35], we next investigated whether over-
expression of LOXL2 alone can elicit oncogenic activity
in the MCF10A cells. We carried out a soft agar assay
for anchorage-independent cell growth. The metastatic
human breast cancer cell line MDA-MB-231 was used
as a positive control for colony formation in soft agar.
After 3 weeks in culture, neither the 10A cont nor the
10A L2 cells proliferated in soft agar (Supplementary
Figure 1), suggesting that LOXL2 expression alone can-
not drive complete oncogenic transformation in the nor-
mal 10A cells.
These findings indicate that increased LOXL2 expres-
sion in normal mammary epithelial cells sustains prolif-
eration, represses apoptosis, and disrupts polarization.
These are all hallmarks of cancer cells [36], suggesting
that aberrant expression of LOXL2 may drive normal
mammary epithelial cells to behave like cancer cells;
however, LOXL2 alone is not sufficient to drive com-
plete oncogenic transformation.
LOXL2 expression activates ErbB2 signaling
We noted the similarity between the morphology of
LOXL2-expressing acini and ErbB2 activation in acini
[35]. This led us to investigate whether LOXL2-
mediated aberrant acini formation occurs through
ErbB2 signaling. We performed Western blotting on
cell lysates from cells plated on Matrigel-coated plates,
and noted elevated phospho-ErbB2 in the 10A L2 cells
compared with the 10A cont cells (Figure 3A). Consis-
tently, we observed elevated phospho-Akt (PKB), a
known downstream marker of ErbB2 activation [37,38],
in the 10A L2 cells compared with 10A cont cells
(Figure 3A). We also observed increased pErk1/2 levels
in the 10A L2 cells, suggesting that the Ras-MAPK
pathway was also activated. Previous reports have
demonstrated the role of intracellular LOXL2 in cancer
progression and cell polarity [25,39], and indeed, in our
cells, the stable expression of LOXL2 increases intra-
cellular LOXL2 levels in MCF10A cells (Supplementary
Figure S2A). Thus the effects of LOXL2 on acinar
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Figure 2 LOXL2 expression disrupts normal breast epithelial acini formation. 10A cont and 10A L2 cells were plated on top of a thin layer
of 50 μl Matrigel in eight-well chamber slides in a suspension of Matrigel/culture media mix to investigate the acinar morphogenesis of these
cells. The cultures were allowed to grow for 8, 10, and 13 days, and then fixed and stained with primary antibodies, as described in the different
panels. All data were based on at least three independent experimental repeats. Scale bar, 20 μm. (A) Immunofluorescence staining of acini with
anti-activated caspase-3 antibody to detect apoptotic cells on day 8 reveals decreased apoptosis in the central cells of the L2 acini.
Representative images of activated caspase-3 staining in acini for each cell line are shown. Quantification represented average percentage ±
standard error of acini containing activated caspase-3-positive cells (P = 0.0007). (B) Immunofluorescence staining of acini with anti-Ki67 antibody
to detect proliferating cells on day 13 reveals that L2 acini had more proliferative cells. Representative images of Ki67-positive acini from each
cell line are shown. Quantification represented average percentage ± standard error of acini containing Ki67-positive cells. (P = 0.0007). (C)
Immunofluorescence staining of acini with anti-GM130 antibody to assess cell polarity on day 10. Representative images of GM130 staining in
acini for each cell line are shown. Quantification represented average percentage ± standard error of acini forming a regular ring structure, as
assessed by GM130 staining (P = 0.0005; n = 80 acini for each cell line per repeat). (D) Quantification of average percentage of acini at day 13
with evacuated lumens ± standard error. Acini with evacuated lumens were defined as having no more than 20% of total number of cells, as
well as Ki67-positive cells present in the center (P = 0.013).
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morphology and ErbB2-related signaling events may be
due to intracellular LOXL2.
To distinguish the effects of extracellular LOXL2 on
these signaling events, we treated Matrigel-plated 10A
cont cells with recombinant human LOXL2 (rhLOXL2).
In this setting, we also observed elevated levels of phos-
pho-ErbB2 (Figure 3B), indicating that extracellular
LOXL2 can induce ErbB2 phosphorylation. The reduc-
tion in total ErbB2 after overnight rhLOXL2 treatment
is likely the result of a feedback mechanism to compen-
sate for increased signalling from the receptor due to
the presence of rhLOXL2. This reduction was not
observed in the 10A L2 cells and may thus be a result
of the cells reaching homeostasis in terms of ErbB2
expression because of long-term exposure to LOXL2.
We used the ErbB2-specific inhibitor Herceptin (Her)
to investigate the role of ErbB2/Her2 in mediating the
observed effects of LOXL2 expression. It was previously
reported that when used at a concentration of 338 nM,
Herceptin kills 10% of MCF7 cells, a breast epithelial
cancer cell line with low ErbB2 expression levels [40].
We observed no differences in the proliferation of 10A
cont and L2 cells at this concentration (data not
shown), consistent with the nonamplified ErbB2 status
of the MCF10A cell line; thus we proceeded with a
treatment concentration of 300 nM at day 6 of culture,
Figure 3 LOXL2 expression in MCF10A cells increases phosphorylation of ErbB2. Cells were plated on a thin layer of Matrigel and serum-
starved for 3 hours before being subjected to serum-blasting and subsequent lysis of cells. (A) Western blotting revealed that phospho-ErbB2
was elevated in 10A L2 cells when compared with 10A cont cells, whereas total ErbB2 levels were equivalent in the two lines, suggesting
increased phosphorylation of ErbB2 in the 10A L2 cells. Densitometry analysis was calculated for pErbB2 levels relative to total ErbB2 and
revealed a significant increase in 10A L2 cells (P = 0.0241). The levels of phospho-Akt and phospho-Erk1/2 were also elevated in 10A L2 cells. (B)
The 10A cont cells were subjected to 16-hour treatment with 50 nM recombinant human LOXL2 (rhLOXL2; R&D Systems) followed by serum-
starvation and serum-blasting (10A cont + rhLOXL2). Western-blotting analysis showed that in 10A cont treated with rhLOXL2, phospho-ErbB2
level was increased to a greater extent than 10A L2 cells when compared with sham-treated 10A cont cells. Densitometry analysis was
calculated for pErbB2 levels relative to total ErbB2 and revealed significant increase in 10A cont + rhLOXL2 cells (P = 0.0438). This suggested that
extracellular recombinant LOXL2 was capable of activating the ErbB2 receptor in 10A cells.
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with the equivalent amount of human IgG added as
controls. Western blot analysis showed that phosphory-
lation of ErbB2 was inhibited at this concentration (Sup-
plementary Figure S2B).
Inhibition of ErbB2 restores the normal phenotype in
LOXL2-expressing acini
Herceptin was added on day 6 of acini culture, with
equivalent dilution of human kappa IgG added to con-
trols. IgG-treated 10A L2 acini showed a reduced level
of apoptosis (Figure 4A), as observed in the untreated
10A L2 acini (Figure 2A). Inhibition of ErbB2 by using
Herceptin significantly induced apoptosis in the central
cells of these acini (P < 0.05; Figure 4D), to a level
equivalent to that seen in IgG-treated 10A cont acini
(Figure 4D, left panel). Apoptosis in 10A cont acini was
unaffected by Herceptin treatment (Figure 4A).
Ki67 staining in 10A L2 acini treated with IgG
remained high, as observed in untreated acini, whereas
10A L2 acini treated with Herceptin exhibited signifi-
cantly decreased Ki67 expression (P < 0.01; Figure 4D),
which was comparable to the 10A cont acini (Figure 4B).
The alignment of the Golgi apparatus in 10A L2 acini
was also restored in response to Herceptin treatment,
such that a classic ring-like staining pattern similar to
control acini was observed (Figure 4C). In contrast, the
Golgi apparatus in IgG-treated 10A L2 acini retained the
scrambled and disorganized staining pattern observed in
untreated 10A L2 acini. Quantification revealed that the
polarity of 10A L2 acini treated with Herceptin was com-
parable to that of control acini (P < 0.005, Figure 4D),
and 10A cont acini were unaffected by Herceptin treat-
ment (Figure 4D, right panel). These findings suggest
that inhibition of ErbB2 blocks the effects of LOXL2 on
mammary epithelial cell polarization. In this model, the
10A L2 acini appear more responsive to Herceptin than
10A cont acini, likely because of the constitutive high
levels of ErbB2 activation present in these cells driven by
elevated levels of LOXL2, whereas 10A cont acini do not
have LOXL2-driven overactivation of ErbB2.
To verify that the differences observed in the acini
after Herceptin treatment were indeed due to inhibition
of ErbB2, we used lapatinib, a dual ErbB1/ErbB2 small-
molecule inhibitor, as an additional treatment. It has
been previously reported that in MCF10A cells, the IC50
concentration for lapatinib is 800 nM [41]. We observed
no differences in the proliferation of 10A cont and L2
cells at this concentration (data not shown), and an
effect on the 10A L2 cells is found only at 5 μM. Wes-
tern blot analysis revealed that 5 μM was needed to
inhibit ErbB2 phosphorylation in the 10A L2 cells (Sup-
plementary Figure S2C). The elevated total ErbB2 levels
are likely due to a feedback mechanism used by the cell
to compensate for decreased receptor signaling.
Activated caspase-3, Ki67, and GM130 staining
revealed that 10A L2 acini reverted to a more-normal
phenotype when treated with lapatinib (Figure 5A
through C, respectively), confirming our findings with
Herceptin, and showing that inhibition of ErbB2 blocks
LOXL2-mediated formation of aberrant mammary acini.
Interestingly, a significant decrease in Ki67 staining (P <
0.05) was seen between DMSO-treated 10A cont acini
and those treated with lapatinib, suggesting that lapati-
nib affects normal mammary epithelial cell proliferation
(Figure 5D, middle panel). However, lapatinib has a
greater efficacy on 10A L2 acini, consistent with higher
levels of phospho-ErbB2 in the 10A L2 cells. Of interest,
we noted a slight decrease in LOXL2 mRNA expression
in response to ErbB2 inhibition (data not shown), con-
sistent with a previous report [42], in which it was
demonstrated that ErbB2 may regulate LOXL2 levels,
suggesting the presence of a feed-forward mechanism.
We showed that Herceptin inhibited ErbB2 signaling
in the 10A L2 cells, and reverted the aberrant 10A L2
acinar phenotype to a more-normal phenotype, suggest-
ing that the LOXL2-induced effect on acinar morpho-
genesis was due to ErbB2 signaling. These results were
verified by using lapatinib. Taken together, these find-
ings show that blocking ErbB2 alone is sufficient to
revert the disorganized morphology of 10A L2 acini to a
normal morphology similar to that of 10A cont acini.
The increase of pErk1/2 in the 10A L2 cells (see Figure
3A) is likely due to activation of ErbB2; it is known that
phosphorylation of ErbB2 can be coupled to the Ras-
MAPK pathway [43,44].
Inhibition of ErbB2 prevents LOXL2-expressing cells from
forming branched structures on Matrigel, and LOXL2
promotes invasion of normal breast epithelial cells
When plated on top of a thin layer of Matrigel (2D on
matrix), 10A L2 cells formed branching structures,
whereas 10A cont cells remained small and round
(Figure 6A, left panel). We counted branch points as a
quantification of branching structures, and 10A L2 cells
showed significantly more branch points than did 10A
cont cells (P <0.001; Figure 6A, right panel). For 10A
cont cells, very little branching was observed in both
hIgG- and Herceptin-treated samples, whereas Hercep-
tin treatment of 10A L2 cells significantly decreased the
extensive branching, and cells formed smaller and more
discrete clusters, similar to the 10A cont cells (P < 0.05;
Figure 6B). The extensive branching networks observed
in 10A L2 cells were also abrogated by treatment with
lapatinib (P < 0.001; Figure 6C). The slight decrease in
10A L2 branching as a result of DMSO treatment, as
well as the slight induction of clustering of 10A cont
cells under hIgG treatment, is likely due to nonspecific
stress responses elicited by the cells toward these
Chang et al. Breast Cancer Research 2013, 15:R67
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Figure 4 Treatment with the ErbB2-specific inhibitor trastuzumab (Herceptin) restores LOXL2-expressing acini phenotype to a more
normal phenotype. Acini were cultured as described in Figure 2; 300 nM Herceptin (Her) dissolved in water was added to cells at day 6 (10A
cont+her; 10A L2+her), and an equivalent amount of human IgG was added as a control (10A cont+hIgG; 10A L2+hIgG). Acini were fixed,
stained, quantified, and presented as described in Figure 2. All data are based on at least three independent experimental repeats. Scale bar, 20
μm. (A) Immunofluorescence staining of acini with anti-activated caspase-3 antibody to detect apoptotic cells on day 8. Staining revealed
increased activation of caspase-3 in 10A L2+her acini when compared with 10A L2+hIgG acini. (B)Immunofluorescence staining of acini with
anti-Ki67 antibody to detect proliferating cells on day 13. Staining revealed a decrease in proliferating cells in 10A L2+her acini when compared
with 10A L2+hIgG acini. (C) Immunofluorescence staining of acini with anti-GM130 antibody to assess cell polarity on day 10. Staining revealed
GM-130 ring-like staining effect in 10A L2+her acini, compared with the scrambled and disorganized staining observed in 10A L2+hIgG acini. (D)
Quantitative analysis of activated caspase-3 staining (left panel; P = 0.0364 for 10A cont+hIgG and 10A L2+hIgG; P = 0.0189 for 10A L2 ± her),
Ki67 staining (middle panel; P = 0.0268 for 10A cont+hIgG and 10A L2+hIgG; P = 0.0073 for 10A L2 ± her), and GM130-ring structures (right
panel; P = 0.0083 for 10A cont+IgG and 10A L2+IgG; P = 0.0007 for 10A L2 ± her) in acini. These results suggest that Herceptin treatment of 10A
L2 acini significantly reverted the acinar morphology to a more-normal phenotype.
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Figure 5 The dual ErbB1/ErbB2 inhibitor lapatinib reverts LOXL2-mediated acinar morphologic changes to a more-normal phenotype.
Acini were cultured as described in Figure 2; 5 μM lapatinib (lap) dissolved in DMSO was added to cells at day 6 (10A cont+lap; 10A L2+lap),
and equivalent amounts of DMSO were added as a control (10A cont+DMSO; 10A L2+DMSO). Acini were fixed, stained, and quantified as
described. All data are based on at least three independent experimental repeats. Scale bar, 20 μm. (A) Immunofluorescence staining of acini
with anti-activated caspase-3 antibody to detect apoptotic cells on day 8. Staining revealed increased activation of caspase-3 in 10A L2+lap acini
when compared with 10A L2+DMSO acini. (B) Immunofluorescence staining of acini with anti-Ki67 antibody to detect proliferating cells on day
13. Staining revealed a decrease in proliferating cells in 10A L2+lap acini when compared with 10A L2+DMSO acini. (C) Immunofluorescence
staining of acini with anti-GM130 antibody to assess cell polarity on day 10. Staining revealed GM-130 ring-like staining effect in 10A L2+lap
acini, compared with the scrambled and disorganized staining observed in 10A L2+DMSO acini. (D) Quantitative analysis of activated caspase-3
staining (left panel; P = 0.00047 for 10A cont+DMSO and 10A L2+DMSO; P = 0.0006 for 10A L2 ± lap), Ki67 staining (middle panel; P = 0.00032
for 10A cont+DMSO and 10A L2+DMSO; P = 0.0257 for 10A cont ± lap; P = 0.00013 for 10A L2 ± lap), and GM130-ring structures (right panel. P
= 0.00016 for 10A cont+DMSO and 10A L2+DMSO; P = 0.0013 for 10A L2 ± lap) in acini. These results suggest that lapatinib treatment of 10A
L2 acini significantly reverted the acinar morphology to a more-normal phenotype.
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Figure 6 LOXL2-expressing MCF10A cells form ErbB2-dependent branching structures on matrix. (A) When plated on Matrigel-coated
plates, 10A cont cells remained small and discrete, whereas 10A L2 cells formed extensive branching structures. Quantification of branch-points
revealed that 10A L2 cells have significantly more branch-points (right panel; P = 0.00004). (B) Herceptin treatment of the 10A L2 cells
significantly decreased the degree of branching of these cells to that seen for controls (right panel; P = 0.0167 and P = 0.0398, respectively). (C)
Lapatinib treatment of the 10A L2 cells significantly abrogated the branching ability of these cells to that seen for controls (right panel; P =
0.0007 and P = 0.0003, respectively).
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control treatments; however, these responses are minor
in comparison to therapy treatment. These findings sug-
gest that LOXL2 expression drives branching of
MCF10A cells on Matrigel, and inhibition of ErbB2
abrogates this LOXL2-mediated effect.
As branching structures are indicative of an invasive
phenotype [45,46], we investigated the invasive capabil-
ities of these cells. Consistently, we observed that 10A
L2 cells invaded more than control cells through
Matrigel in Transwell invasion assays (Figure 7A).
Moreover, the invasion of 10A L2 cells was signifi-
cantly reduced by treatment with either Herceptin
(Figure 7B) or lapatinib (Figure 7C). These findings are
also in accordance with previous reports that ErbB2
activation induces invasion of MCF10A cells [47]. The
branching morphology was not apparent in the 3D
acini cultures, as confirmed by immunofluorescence
staining of Laminin V, which indicated that the base-
ment membrane was intact in both 10A L2 and 10A
cont acini (Supplementary Figure S3A). It was pre-
viously reported that only acini with ErbB2/ErbB3 dual
overexpression develop invasive structures, whereas
ErbB2-only overexpressing acini have a larger acinar
structure with a filled-in lumen [48]. The branching
morphology present in 10A L2 cells in 2D culture and
lack thereof in the 3D culture suggests that further sig-
nals, such as ErbB3 activation reported by Aceto et al.
[48], may be required for the 3D branching to occur.
Figure 7 LOXL2 promotes invasion of normal breast epithelial cells; this effect is abrogated with ErbB2 inhibition. (A) The 10A L2 cells
exhibited increased invasion through Matrigel compared with 10A cont cells in Transwell invasion assays. (B) Herceptin treatment reduced the
invasive ability of the 10A L2 cells to a level comparable to 10A cont cells. Human IgG treatment had no effect on the invasiveness of the
manipulated 10A cells. (C) Lapatinib treatment of the 10A L2 cells greatly reduced the invasiveness of the cells to a level comparable to the 10A
cont cells. DMSO treatment had no effect on the invasive properties of the manipulated 10A cells.
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The presence of branching structures, as well as
increased invasiveness when plated on top of Matrigel,
suggests that the 10A L2 cells have undergone EMT
[49]. Intracellular LOXL2 has previously been implicated
in mediating EMT [8,26]. Thus, we investigated the
mRNA levels of the EMT markers vimentin, E-cadherin,
N-cadherin, SNAI1, SNAI2, Twist, and a-SMA in 10A
cells plated on top of Matrigel. We found that only
E-cadherin and SNAI1 were significantly downregulated
at the mRNA level in the 10A L2 cells (Supplementary
Figure S3B), suggesting that they may have lost some of
their epithelial features. However, when we assessed
E-cadherin expression in the 3D acinar structures
through immunofluorescence staining, we found that
E-cadherin protein levels were not altered between the
two cell lines (Supplementary Figure S3C). When taken
together, these data suggest that, when plated on matrix
in a 2D system, the 10A L2 cells can undergo only par-
tial EMT, as no mesenchymal markers investigated here
were upregulated. Furthermore, when cultured in 3D
Matrigel suspension, the 10A L2 cells are unable to
maintain this partial EMT phenotype. This suggests that
EMT does not play a role in LOXL2-induced invasive-
ness in our model system.
To assess the role of LOXL2 in invasion of ErbB2-
expressing cancer cells and validate our findings in a
second model, we used the noninvasive ErbB2-overex-
pressing cancer cell line MDA-MB-361. Transwell-inva-
sion assays revealed that these cells exhibited increased
invasion through ECM when treated with rhLOXL2
(Supplementary Figure S3D). We also carried out a
4-day 3D culture of these cells, as described by Kenny et
al., [50], and observed that both MDA-MB-361 control
and rhLOXL2-treated cells form individual cell clusters,
as previously described [50]; thus LOXL2 cannot induce
invasive “stellate” structures or branching morphologies
in 3D (data not shown), consistent with the MCF10A
data. These findings support the theory that further sig-
nals are required, in addition to LOXL2 expression, for
3D invasive structures to form.
Taken together, these results suggest that LOXL2
expression can promote the development of a more-
aggressive cancer-like phenotype in normal mammary
epithelial cells, through ErbB2 activation.
Figure 8 LOXL2 expression induces ErbB2 activation through production of 2O2. (A)Production of H2O2 on Matrigel was measured as an
activity read-out in the 10A cont and 10A L2 cells, by using a commercially available kit and following the manufacturer’s instructions (Abcam).
10A L2 cells produced higher levels of H2O2, as expected, because of LOXL2 overexpression. (B) The 200 U/ml catalase (+cat) was added to
remove H2O2 produced by LOXL2. Western blotting revealed that pErbB2 was decreased in 10A L2 cells treated with catalase (L2+cat) in
comparison with untreated cells (L2). (C) Addition of H2O2 to 10A cont cells strongly induced ErbB2 activation. Taken together, these results
indicate that, by removing H2O2, we can significantly abrogate ErbB2 activation in 10A L2 cells, and addition of H2O2 activated ErbB2.
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LOXL2 activates ErbB2 via reactive oxygen species
production
Next, we investigated how LOXL2 might be mediating
activation of ErbB2. Jung et al. [51] recently demonstrated
that TIMP-1 induces aberrant acinar morphogenesis in
MDCK cells [51]. As we previously showed a strong link
between LOXL2 and TIMP-1 in breast cancer cell inva-
sion [4], we postulated that TIMP-1 may be playing a role
in the aberrant morphogenesis in our system. However,
TIMP-1 protein levels were unchanged between the 10A
cont and L2 lines (Supplementary S3E), suggesting that
TIMP-1 is not involved.
It also was previously demonstrated that increased
matrix stiffness enhances invasiveness of ErbB2-
transformed MCF10A cells [52]. We therefore investigated
whether stiffness plays a role in LOXL2-mediated ErbB2
activation. However, in our model system, increasing
matrix stiffness did not increase ErbB2 activation (data not
shown). Thus, activation of ErbB2 could not be attributed
to regulation of TIMP1 or to altered matrix stiffness.
We observed that LOXL2 activation of ErbB2 occurs
within 15 minutes of stimulation (Supplementary Figure
S4A), suggesting a novel mechanism of activation invol-
ving rapid receptor activation. It was previously shown
that UV can rapidly activate ErbB2 through generation
of reactive oxygen species (ROS) [53,54]. As such, we
hypothesized that LOXL2 may activate ErbB2 through
H2O2 produced as a byproduct of LOXL2 activity. The
activity of LOXL2 is routinely assessed in the form of
H2O2 production [55]. Indeed, we found CM from 10A
L2 to have higher production of H2O2 compared with
that from 10A cont cells (Figure 8A). The activity was
measured in CM added on top of Matrigel, suggesting
that Matrigel is acting as a substrate for LOXL2. We
used catalase, an enzyme that removes H2O2 [56], to
investigate the effects of H2O2 removal on ErbB2 activa-
tion. When 200 U/ml catalase was added to 10A L2
cells, we observed a significant reduction in ErbB2 acti-
vation (Figure 8B and Supplementary Figure S4B) with-
out altering cell viability (data not shown). We
confirmed these findings in 10A cont cells treated with
rhLOXL2 for 15 minutes in the presence or absence of
catalase (Supplementary Figure S4C). Moreover, addi-
tion of H2O2 to 10A cont cells was able to induce
ErbB2 activation, confirming this as the likely mechan-
ism of action (Figure 8C). Taken together, these results
suggest that LOXL2 production of ROS can induce
ErbB2 activation.
LOXL2 expression correlates with metastasis and
decreased survival in ErbB2-overexpressing breast cancer
patients
Further to investigate the link between LOXL2 and ErbB2
and cancer progression in a clinical setting, we used a pre-
viously published dataset and performed a retrospective
study to investigate whether LOXL2 mRNA expression
level is correlated with metastasis and survival of ErbB2-
positive breast cancer patients [17]. We found that
patients with ErbB2-positive tumors expressing high levels
of LOXL2 had a significantly poorer prognosis, with
LOXL2 expression being significantly correlated with
decreased overall survival and decreased metastasis-free
survival in these patients (both P < 0.05; Figure 9A, B,
respectively). The relation between LOXL2, ErbB2, and
metastasis was further validated in a second patient data
set (P ≤ 0.05; Supplementary Figure S5).
We previously reported that LOXL2 expression in
patients with ER- tumors also correlates with metastasis
and decreased survival [4]. Thus, LOXL2 expression is
Figure 9 Elevated LOXL2 and ErbB2 are associated with
invasive cell behavior and poor patient prognosis. (A) Disease-
specific genomic analysis (DSGA) was performed on gene-
expression microarray data from the NKI cohort [17]. Of 295 tumors,
51 were found to express high levels of ErbB2, and a Kaplan-Meier
survival curve is constructed from this subset of ErbB2-positive
tumors. Shown here is the overall survival of patients with Her2/
ErbB2-positive tumors (n = 51) separated into low and high LOXL2
expression. P = 0.017. (B) As in Figure 8A, showing metastasis-free
survival. P = 0.026.
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associated with poor prognosis in breast cancer patients
with different subtypes of the disease. This is consistent
with our observations that LOXL2 increases invasion
and metastasis through the ErbB2-dependent mechan-
isms we present here, and through ErbB2-independent
mechanisms reported previously [4,7].
Conclusion
We showed that, in the immortalized human mammary
epithelial cell line MCF10A increased expression of
LOXL2 interferes with normal acini development by
repressing apoptosis, prolonging proliferation, and abro-
gating polarization of the cells. We further showed that
LOXL2 expression drives the formation of branching
structures on matrix and enhances MCF10A cell inva-
sion. We also demonstrated that ErbB2 is responsible for
mediating LOXL2 effects on cell morphology and beha-
vior, and present here an exciting new mechanism by
which LOXL2 may regulate cellular behavior through
production of ROS. Finally, we showed that high LOXL2
expression correlates with poor prognosis in ErbB2-posi-
tive breast cancer patients, demonstrating a strong link
between LOXL2 and ErbB2 and aggressive cell behavior.
Our findings indicate that high expression of LOXL2 pro-
motes tumor-like phenotype in normal mammary cells
and suggest that LOXL2 may be used as a marker to
identify patients most likely to respond to anti-ErbB2
therapy. In addition, deactivation of ErbB2 may be used
as a marker of response in patients treated with anti-
LOXL2 therapy. Thus, our findings may have important
clinical implications for breast cancer patients.
Additional material
Additional file 1: Supplementary Figure S1. LOXL2 expression does
not induce oncogenic activity. The manipulated MCF10A cell lines
were compared with MDA-MB-231 breast cancer cell line for their ability
to grow in an anchorage-independent manner by using the soft agar
assay. Results indicated that neither of the 10A cell lines can form
colonies in soft agar, unlike the breast cancer cell line MDA-MB-231 (P =
0.00008).
Additional file 2: Supplementary Figure S2. LOXL2 expression and
signaling inhibition in MCF10A cells. (A) Western blot analysis of cell
lysates from 10A cont and 10A L2 cells revealed that intracellular LOXL2
was also increased in the 10A L2 cells. (B) 10A L2 cells were subjected to
overnight treatment with either 300 nM trastuzumab (Herceptin; L2+her)
or the equivalent amount of human IgG (L2+IgG) followed by 3 hours of
serum-starvation and 15 minutes of serum-blasting. Western blot analysis
of the cell lysates revealed that at 300 nM, Herceptin inhibits the
phosphorylation of ErbB2 in the 10A L2 cells. (C) 10A L2 cells were
subjected to overnight treatment at the indicated dosage of lapatinib (0
μM (that is, DMSO only), 1 μM, and 5 μM) followed by 3 hours of serum-
starvation and 15 minutes of serum-blasting. Western blot analysis
indicated that lapatinib inhibits phosphorylation of ErbB2 at only 5 μM
concentration.
Additional file 3: Supplementary Figure S3. LOXL2 does not induce
invasion or EMT in 10A acini, but increases invasiveness of MDA-
MB-361 cells. TIMP-1 levels are not altered by LOXL2 expression. (A)
Acini were cultured as described in Figure 2 and then fixed and stained
with laminin V (Lam-V; Millipore) for the basement membrane and Ki-67.
Representative photos from three independent experimental repeats are
presented. Scale bar, 20 μm. Intact basement membrane, as evidenced
by Lam-V staining, suggested that these cells do not form invasive
structures when cultured in 3D. (B) Quantitative RT-PCR of Vimentin, E-
cadherin, N-cadherin, SNAI1, SNAI2, Twist, and a-SMA in manipulated
MCF10A cells showed that only E-cadherin and SNAI1 mRNA levels were
downregulated in 10A L2 cells. Error bars represent SEM of three
independent experiments. P = 0.00005 for E-cadherin and P = 0.00039
for SNAI1. (C) Acini were cultured as described in Figure 2 and then fixed
and stained with E-cadherin (E-cad, Abcam). Representative photos from
three independent experimental repeats are presented. Scale bar, 20 μm.
10A L2 acini did not have decreased E-cadherin protein levels. (D) The
noninvasive ErbB2-amplified breast cancer MDA-MB-361 cells were
subjected to Transwell invasion assays in the presence or absence of 50
nM rhLOXL2. Results indicated that recombinant LOXL2 increased the
invasiveness of the noninvasive cells. P = 0.0176. (E) Western blot analysis
of TIMP-1 levels in 10A cont and 10 L2 CM. Results indicate that TIMP-1
levels are unchanged between the two cell lines.
Additional file 4: Supplementary Figure S4. Recombinant human
LOXL2 (rhLOXL2) rapidly activates ErbB2, and H2O2 depletion
inhibits this activation. (A) The 10A cont cells were plated out, as
described in Figure 3. After overnight incubation, cells were serum-
starved for 3 hours and stimulated with 50 nM rhLOXL2 for 15 minutes.
Western blot analysis revealed that ErbB2 was activated rapidly.
Densitometry analysis was calculated on pErbB2 expression relative to
Hsc70. (B) Densitometry analysis revealed that catalase treatment
significantly decreased activation of ErbB2 in 10A L2 cells (P = 0.026) and
was calculated on pErbB2 expression relative to ErbB2. (C) Catalase
treatment (cont+rh+cat) abrogated rhLOXL2-mediated ErbB2 activation
in 10A cont cells (cont+rh) (right blot, P = 0.0017 for cont versus cont
+rhLOXL2; P = 0.043 for cont+rhLOXL2 versus cont+rhLOXL2+cat).
Densitometry analysis was calculated on pErbB2 expression relative to
Hsc70.
Additional file 5: Supplementary Figure S5. LOXL2 expression is
correlated with metastasis in breast cancer patients with ErbB2+
tumors. Kaplan-Meier survival curves were constructed for patients with
Her2/ErbB2-positive tumors by using MAS5 parameters, with global
scaling set to 600 [19]. Overall survival (left panel; P = 0.05) and
metastasis-free survival (right panel; P = 0.032) are shown here; n = 88
patients.
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